Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here.
Questions
1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05)
2. Which patient subgroups are most likely to respond to this therapeutic approach? (1:40)
3. What are the major challenges in the manufacturing of CAR-T cells? (3:28)
Ibrahim El Houssieny has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
